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:fhe Errroocan ParlLamenE.
- whereas Ehe rlghE to opEimrn health care is a fundament,al right,
- 
whcread publlc healEh falle wlth tlre scotrte of, Ehe TreaEies,
- 
whereao it is Ehe Eask of Member States and Ehe Coununlty Eo providc
themeelvce wlth structures guaranEeeing Ehe besE poseible health c38€r
- 
whereaa Etre groring use of pharmaceuEical products leads to high costs
for eocial security sYaEema,
- 
lrhetCa} pharmaceutical prOddction is in ttre hands of a few Large
underfakings whlch occuPy a dodnant poaition and make enormous
profits at the Connunity'8 expense,
: whereas Ehe CmmuriEy dlrectives adopted on Ehis subjecE chiefly
concern tlre f,ree movemenE qf Pharmaceutical producEs, which ls,
hdirever, sElll seriously lmpeded by technical barriers to Erade,
1. f s concerned at the ,rrr"onttotled tncrease in Etre nrrrtber of pharna-
ceugipal producEs being puE on Ehe narkeE and the variety of forms' Ln
which t[ey appear, wiE]tout, any evidence ttrat, this guantiEative
increage ls producing a percepEible lmprovement in the quallEy of
healEh or hea1Eh ProtecEion;
2. conei[ers Ehat measureE need to be Eaken against Ehe overconsr.mption
of phrrrmaceuEical producEs due Eo cqnrnercial pracBieeg, in parEicualr
adverElsing by phararaceutical laboratories, so as to prevent Ehe
wastalge, harmful side effects and exEra burden on the Eocial security
sysfena;
3. Stres,see Etre need for a Eransparent market for pharmaceutical producEs
by meana of quality and prlce controls in order Uo PUE a sEoP to
excegsive proflEs;
4. Poin!,g out Ehe existence of, :rnd Erade in, illegally imported prodrrcts
and rrrgently requests Ehe CimmieEion to sEart the neceesary LnvesEiga-
tion and tso take effecEive action;
5. Ig of Ehe opinlon thaE the price of pharmaceuEieal producEs ought
not to be allowed Eo becme a social obsEacle Eo Ehe right to opt'imum
health c:rrei
6. SUeJacs therefore Elre need for Ehe etrict applicaEion on the rulea
of cfpetition;
7. Recalle Etrc need to reorlentate policy regarding pharmaceuElcal producEs
eo tsl[at inducEriat intereets ale no longer Ehe only maEter to whlch
inpoqtance is aEtached but also coordinaEion between pharmaccutical
laboratories, privage and government reseatch institutes and Ehe docEora
conceraed, in the inEerests of Etre conaumeri
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8. Urgea thi rapid harmonlzatl.on and raiei.ngrof sEandards in registratLon
of pharnaesutical producta eo that, the dlfferences beEween llember
SEatea al regardg what product,s are available on or off prescription
cease Eo e:elst,;
9. IE of the opinion that, the consumer is entitled Eo verified infor-
mation on ttre packaglng and enclosureai
10. Requests ure conunission to proceed wlthout, delay with its proposar
, on misleadlng advertising for pharmaeeuEical products;
11- Considerg iE eesential Ehat a proposal be reeeived frqn the cqruuission
i.n t'he nea^r futr:re on a well-conceived infornation and education
campaigm govering the proper use of pharnaceutical products and the
liniEs.tC be placed on ttrelr uaei
12. trges that more attention be paid to the. polrits mentioned above in
Eraining and fr:rther Erainlng courEes for doctors, nursing staff and
pharnaclaitg,, so thaE arl persona using or prescribing medicines
have avaLlable all ttre necesaary informatLon on Ehe therapeutic value
of Ehe products proposed to Ehem;
13. Deploree the way in which many pha:rmaceutical conpanies, through their
medicar r,epreeentativea, freguently see flt to offer ttreir producta
f,or sale Eo docEors by means of samples, gifts and loane, and calls
oh the cdrmi.ssion to draw up a propoEal desigmed to prevent, the use
orf Ehege i,nproper sales practices in the various lrtenrber States;
14. Conslders that, pharmaceutlcal products exported to developing counEries
must satisfy the sane safety and quality standaadg as Ehose applicable
in the Member States of Etre ConmruriEy;
15. InsLructs Ehe cmnisEion to harmonize the statlstical information
cornpretely and to aaaryse this in a report, on the pharmaceutical
sector, so EhaE a sound overall picture may be gained of Ehe consurnp-
tLon of pharmaceutical products anil ttre conaeqluenees thereof for
public health.
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